ArticleIndian journal of endocrinology and metabolism
Randomized Placebo Control Study of Metformin in Psoriasis Patients with Metabolic Syndrome (Systemic Treatment Cohort).
Article in Indian journal of endocrinology and metabolism. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT03629639 (Metformin for Treatment of Psoriasis Combined With Disorders of Glucose and Lipid Metabolism), which is not on this map. Cited by 15 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Metformin for Treatment of Psoriasis Combined With Disorders of Glucose and Lipid Metabolism: A Double-Blind, Randomized, Placebo-Controlled Study
Who cites it
15 citing papers in PubMed, 35 citations in OpenAlex.
- Efficacy and safety of different doses of apremilast in mild to-moderate psoriasis: A randomized controlled study.Indian journal of pharmacology · 2026Trial
- Hypoxia and oxidative stress related to inflammation and vascular aspects of the pathogenesis of psoriasis.Skin health and disease · 2026Review
- Inflammaging and Senescence-Associated Secretory Phenotype (SASP) in Psoriasis - A Narrative Review of Potential Mechanisms and Anti-Inflammaging Strategies.Psoriasis (Auckland, N.Z.) · 2026Review
- Metformin: Old Drug, New Therapeutic Potential in the Skin? A Brief Narrative Review.Advances in therapy · 2025Review
- Exploring the Effects of Metformin on the Body via the Urine Proteome.Biomolecules · 2025Article
- Cardiovascular Considerations and Implications for Treatment in Psoriasis: An Updated Review.Vascular health and risk management · 2024Review
- The efficacy of metformin for the treatment of psoriasis: a meta-analysis study.Postepy dermatologii i alergologii · 2023Review
- The Combined Use of Metformin and Methotrexate in Psoriasis Patients with Metabolic Syndrome.Dermatology research and practice · 2022Article
- The Antidiabetic Agent Metformin Inhibits IL-23 Production in Murine Bone-Marrow-Derived Dendritic Cells.Journal of clinical medicine · 2021Article
- Clinical effects of antidiabetic drugs on psoriasis: The perspective of evidence-based medicine.World journal of diabetes · 2021Article
- Is Metformin a Possible Beneficial Treatment for Psoriasis? A Scoping Review.Journal of personalized medicine · 2021Article
- High-Density Lipoprotein (HDL) in Allergy and Skin Diseases: Focus on Immunomodulating Functions.Biomedicines · 2020Review
- Metformin ameliorates animal models of dermatitis.Inflammopharmacology · 2020Article
- Metformin inhibits IL-1β secretion via impairment of NLRP3 inflammasome in keratinocytes: implications for preventing the development of psoriasis.Cell death discovery · 2020Article
- Psoriasis and Cardiovascular Comorbidities: Focusing on Severe Vascular Events, Cardiovascular Risk Factors and Implications for Treatment.International journal of molecular sciences · 2017Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundPsoriasis has been found to be associated with obesity, metabolic syndrome (MS), diabetes, and cardiovascular risk factors. Metformin treatment showed improvement in cardiovascular risk factors and hyperinsulinemia.
objectiveTo evaluate the efficacy and safety of metformin in psoriasis patients with MS. MATERIALS AND
methodsThis was a single-center, parallel-group, randomized, open-label study with blinded end point assessment of metformin (1000 mg once daily for 12 weeks;
resultsStatistically significant improvement was observed in mean percentage change in erythema, scaling, and induration (ESI) (
conclusionMetformin has shown improvement in psoriasis and parameters of MS, hence can be used for the benefit of psoriasis patients having MS. Large, controlled studies are needed to confirm.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.